Investor Presentaiton

Numerous levers to drive long-term growth $ Extended durability of our 10 business with subcutaneous nivolumab and Opdualag Increasingly de-risked the New Product Portfolio 稟 Registrational portfolio increasing from 6 to 12 new assets over the next 18 months Developing medicines in rapidly growing markets with significant commercial opportunities Leading positions with differentiated platforms in Cell Therapy and Targeted Protein Degradation Strategic optionality from Business Development Clearly establish BMS as an R&D leader by the end of the decade Ill Bristol Myers Squibb™ Not for Product Promotional Use 136

View entire presentation